Landmark Sabra North America deployment targeting 20k beds
| Stock | Painchek Ltd (PCK.ASX) |
|---|---|
| Release Time | 14 Apr 2026, 9:19 a.m. |
| Price Sensitive | Yes |
Landmark Sabra North America deployment targeting 20k beds
- Sabra, a $5b Nasdaq-listed healthcare REIT, to fund PainChek across its 329 facilities
- Pricing agreement of $55-75 USD per bed per annum
- Sabra to introduce PainChek to all current & future operators in its network
PainChek Ltd (ASX: PCK), developer of the world's first AI-powered pain assessment and monitoring application, has entered into a Master Services Agreement with Sabra Health Care REIT, Inc. (Nasdaq: SBRA), a leading owner of healthcare real estate assets across North America. Under the agreement, Sabra will fund the cost of PainChek's solution on behalf of its operating partners, significantly reducing barriers to adoption at the operator level. The pricing agreement ranges from $55-$75 USD per bed per annum, with the lower end pricing only available for clients with long-term agreements (2-3 years) or who participate in a collaborative research or outcomes publication project with PainChek. This is a perpetual agreement with the option for either party to terminate with 90 days' notice after the initial 12-month period. Sabra is obligated to introduce PainChek to all current and future operators within its portfolio. The owner-level endorsement and financial support materially increase the likelihood of operator uptake, streamlining sales cycles and deployment and enabling PainChek to pursue broad portfolio penetration without proportional increases in sales and marketing investment. Sabra has a market capitalisation of approximately $5 billion, placing it among the larger specialised healthcare REITs in North America, having more than 36,000 beds or units in the US and Canada. PainChek believes this owner-led pricing and distribution model is highly replicable across other REITs and institutional asset owners, supporting the Company's strategy to scale efficiently in the North American market.
PainChek believes this owner-led pricing and distribution model is highly replicable across other REITs and institutional asset owners, supporting the Company's strategy to scale efficiently in the North American market.